[go: up one dir, main page]

NO20062387L - Novel imaging agents - Google Patents

Novel imaging agents

Info

Publication number
NO20062387L
NO20062387L NO20062387A NO20062387A NO20062387L NO 20062387 L NO20062387 L NO 20062387L NO 20062387 A NO20062387 A NO 20062387A NO 20062387 A NO20062387 A NO 20062387A NO 20062387 L NO20062387 L NO 20062387L
Authority
NO
Norway
Prior art keywords
imaging agents
novel imaging
novel
agents
imaging
Prior art date
Application number
NO20062387A
Other languages
English (en)
Inventor
Duncan Hiscock
Ben Newton
Benedicte Gilbert
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20062387L publication Critical patent/NO20062387L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/0429Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K51/0431Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
NO20062387A 2003-11-26 2006-05-24 Novel imaging agents NO20062387L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327494.1A GB0327494D0 (en) 2003-11-26 2003-11-26 Novel imaging agents
PCT/GB2004/005003 WO2005053752A2 (en) 2003-11-26 2004-11-26 Novel imaging agents comprising caspase-3 inhibitors

Publications (1)

Publication Number Publication Date
NO20062387L true NO20062387L (no) 2006-05-31

Family

ID=29797853

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062387A NO20062387L (no) 2003-11-26 2006-05-24 Novel imaging agents

Country Status (15)

Country Link
US (1) US20060275215A1 (no)
EP (1) EP1763371A2 (no)
JP (1) JP2007512302A (no)
KR (1) KR101236124B1 (no)
CN (1) CN1905904B (no)
AU (1) AU2004294784B2 (no)
BR (1) BRPI0416938A (no)
CA (1) CA2547236A1 (no)
GB (1) GB0327494D0 (no)
IL (1) IL175667A (no)
MX (1) MXPA06006045A (no)
NO (1) NO20062387L (no)
RU (1) RU2006117819A (no)
WO (1) WO2005053752A2 (no)
ZA (1) ZA200603887B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773762B1 (en) * 2004-07-08 2010-11-10 Aposense Ltd. Methods and compounds for detection of medical disorders
CA2594770C (en) * 2005-01-17 2013-10-15 Universitatsklinikum Munster 5-pyrrolidinylsulfonyl isatin derivatives
GB0502277D0 (en) * 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
AU2006306592A1 (en) * 2005-10-21 2007-05-03 Immunochemistry Technologies, Llc In vivo detection of apoptosis
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
JP5916039B2 (ja) * 2006-06-21 2016-05-11 ジーイー・ヘルスケア・リミテッド 放射性医薬品製品
GB0612333D0 (en) * 2006-06-21 2006-08-02 Ge Healthcare Ltd Radiopharmaceutical products
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
KR100845010B1 (ko) * 2007-08-29 2008-07-08 한국생명공학연구원 Nir/mr 이중모드 분자영상용 고분자 입자 및 그제조방법
CA2975841C (en) * 2008-04-30 2021-05-25 Siemens Medical Solutions Usa, Inc. Substrate based pet imaging agents
US20110165611A1 (en) * 2008-09-04 2011-07-07 Chun Li Dual modality detection of apoptosis
EP2367816B1 (en) 2008-09-05 2016-11-09 Imperial Innovations Limited Isatin derivatives for use as in vivo imaging agents
GB0818738D0 (en) * 2008-10-13 2008-11-19 Ge Healthcare Ltd Imaging neuroflammation
WO2014186737A1 (en) * 2013-05-16 2014-11-20 The Johns Hopkins University Compositions and methods for chemical exchange saturation transfer (cest) based magnetic resonance imaging (mri)
WO2017053864A1 (en) * 2015-09-23 2017-03-30 Intracellular Technologies, Llc Cysteine protease inhibitors
CN107655871A (zh) * 2017-09-12 2018-02-02 重庆医科大学 一种阿仑膦酸钠的高灵敏宽检测范围荧光检测新方法
WO2023108009A1 (en) * 2021-12-08 2023-06-15 Cytosite Biopharma Inc. Compounds specific to granzyme b and uses thereof
TW202508601A (zh) * 2023-06-07 2025-03-01 美商塞托賽特生物製藥股份有限公司 對顆粒酶b具有特異性之化合物之前驅藥及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601801A (en) * 1994-08-02 1997-02-11 Merck Frosst Canada, Inc. Radiolabelled angiotensin converting enzyme inhibitors
AR016384A1 (es) * 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
NO20002644D0 (no) * 2000-05-23 2000-05-23 Nycomed Imaging As Kontrastmiddel
EP1283728A2 (en) * 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
JP4190290B2 (ja) * 2001-03-02 2008-12-03 ユニバーシティー オブ ウエスタン オンタリオ 放射能標識された化合物のポリマー前駆体、ならびにその作製および使用法
WO2004028449A2 (en) * 2002-09-24 2004-04-08 The General Hospital Corporation Azulene dimer-quenched, near-infrared fluorescent probes
JP2006519777A (ja) * 2003-02-07 2006-08-31 メルク フロスト カナダ リミテツド 活性部位プローブとしての不可逆的カスパーゼ3インヒビター
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa

Also Published As

Publication number Publication date
ZA200603887B (en) 2008-02-27
BRPI0416938A (pt) 2007-02-13
EP1763371A2 (en) 2007-03-21
CA2547236A1 (en) 2005-06-16
CN1905904A (zh) 2007-01-31
GB0327494D0 (en) 2003-12-31
IL175667A (en) 2013-09-30
AU2004294784A1 (en) 2005-06-16
MXPA06006045A (es) 2006-08-23
AU2004294784B2 (en) 2008-04-24
CN1905904B (zh) 2011-12-21
KR20060123196A (ko) 2006-12-01
WO2005053752A3 (en) 2005-10-06
KR101236124B1 (ko) 2013-02-21
WO2005053752A2 (en) 2005-06-16
RU2006117819A (ru) 2008-01-10
JP2007512302A (ja) 2007-05-17
US20060275215A1 (en) 2006-12-07
IL175667A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
ATE354631T1 (de) Nuancierungsmittel
DE602004019373D1 (de) Bilderzeugungsverfahren
DE602004001570D1 (de) Bilderzeugungsvorrichtung
ATE363383T1 (de) Schlingenware
ITMI20041123A1 (it) Fissaggio
AT502792A5 (de) Düsenanpressvorrichtung
DE602004030111D1 (de) Bilderzeugungsvorrichtung
NO20062387L (no) Novel imaging agents
IS8309A (is) Lyfjablöndur
DE602004021466D1 (de) Bilderzeugungsvorrichtung
DE112004000620D2 (de) Struktoguss
DE502004000672D1 (de) Pigmentpreparationen
DE10355350A8 (de) Elektromodul
DE502004001524D1 (de) Hydrolager
ATA662003A (de) Trink-mundstück
ATE446959T1 (de) Chromenonindole
DE502004001629D1 (de) Bremsenprüfstand
ATE444953T1 (de) Substituierte spirobenzazepine
DE502004000518D1 (de) Mitgängergabelhubwagen
DE112004002227D2 (de) Nietverarbeitungsgerät
DE602004026020D1 (de) Bildaufnahmegerät
DE10394329D2 (de) Mäanderstent
DE60330055D1 (de) Bildaufzeichnungsvorrichtung
ATE406350T1 (de) Prolinylarylacetamide
DE10329218B4 (de) Hotflue

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application